13 results match your criteria: "Civil Hospital "SS.Giovanni e Paolo"[Affiliation]"
Stroke
December 2024
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy (M.F., E.D.M., F.D.S., F. Pistoia, R.O., S.S.).
Background: Sex may impact clinical outcomes in patients with stroke treated with dual antiplatelet therapy (DAPT). We aimed to investigate the sex differences in the short-term outcomes of DAPT within a real-world population of patients with noncardioembolic mild-to-moderate ischemic stroke or high-risk transient ischemic attack.
Methods: We performed a propensity score-matched analysis from a prospective multicentric cohort study (READAPT [Real-Life Study on Short-Term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack]) by including patients with noncardioembolic mild-to-moderate stroke (National Institutes of Health Stroke Scale score of 0-10) or high-risk transient ischemic attack (age, blood pressure, clinical features, duration of transient ischemic attack, presence of diabetes [ABCD] ≥4) who initiated DAPT within 48 hours of symptom onset.
Int J Stroke
December 2024
Department of Brain Sciences, Imperial College London, London, UK.
Background: According to the literature, about one third of patients with brain ischemic symptoms lasting <24 h, which are classified as Transient ischemic attacks (TIAs) according to the traditional "time-based" definition, show the presence of acute ischemic lesions at neuroimaging. Recent evidence has shown that the presence of acute ischemic lesions at neuroimaging may impact on the outcome of patients with transient ischemic symptoms treated with dual antiplatelet treatment (DAPT). This uncertainty is even more compelling in recent years as short-term DAPT has become the standard treatment for any non-cardioembolic TIA or minor ischemic stroke.
View Article and Find Full Text PDFInt J Stroke
December 2024
Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, L'Aquila, Italy.
J Neurol Sci
November 2024
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Background: The optimal treatment for acute minor ischemic stroke is still undefined. and options include dual antiplatelet treatment (DAPT), intravenous thrombolysis (IVT), or their combination. We aimed to investigate benefits and risks of combining IVT and DAPT versus DAPT alone in patients with MIS.
View Article and Find Full Text PDFDermatology
December 2024
Department of Health Science, Section of Dermatology, University of Firenze, Firenze, Italy.
Eur Stroke J
December 2024
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
J Clin Med
August 2023
Schepens Eye Research Institute, Mass Eye and Ear, Boston, MA 02114, USA.
Objective: We sought to evaluate the clinical outcomes of hemi-UT-DSAEK grafts from the pediatric donor corneas of patients affected by Fuchs Endothelial Corneal Dystrophy (FECD).
Methods: A prospective, interventional case series was conducted at the Ophthalmology Department of Venice Civil Hospital and the Veneto Eye Bank Foundation (Venice, Italy). Six eyes of six patients affected by FECD received large-diameter, semicircular hemi-UT-DSAEK grafts obtained from three pediatric donor corneas using the standard pull-through method.
Dermatol Ther
September 2021
UOC di Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Topical treatment is the mainstay for mild or moderate psoriasis, but patients are generally little satisfied. Calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam has shown to improve signs and symptoms in plaque psoriasis patients. This study assessed patient's satisfaction with Cal/BD foam in a real-life Italian dermatological clinical practice.
View Article and Find Full Text PDFFront Oncol
March 2021
Department of Medicine DIMED, Pathology and Cytopathology Unit, University of Padova, Padova, Italy.
Background: Screening significantly reduces mortality from colorectal cancer (CRC). Screen detected (SD) tumors associate with better prognosis, even at later stage, compared to non-screen detected (NSD) tumors. We aimed to evaluate the association between diagnostic modality (SD vs.
View Article and Find Full Text PDFInfez Med
June 2019
Microbiology Unit, Clinical Pathology Department, Hospital dell'Angelo, Mestre (Venice), Italy.
We describe the first Italian case of Shewanella algae septicemia in an immunocompetent patient with chronic leg ulcers. The patient had been exposed to seawater before the onset of symptoms. Despite the absence of severe underlying diseases, the primary soft tissue infection of the leg was complicated by hematogenous dissemination.
View Article and Find Full Text PDFWorld J Virol
August 2015
Pierluigi Brugnaro, Erika Morelli, Francesca Cattelan, Andrea Petrucci, Sandro Panese, Franklyn Eseme, Francesca Cavinato, Andrea Barelli, Enzo Raise, Infectious Diseases Department, Civil Hospital "SS.Giovanni e Paolo", 6776-30122 Venice, Italy.
Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection has been widely available in industrialized countries since 1996; its widespread use determined a dramatic decline in acquired immunodeficiency syndrome (AIDS)-related mortality, and consequently, a significant decrease of AIDS-defining cancers. However the increased mean age of HIV-infected patients, prolonged exposure to environmental and lifestyle cancer risk factors, and coinfection with oncogenic viruses contributed to the emergence of other malignancies that are considered non-AIDS-defining cancers (NADCs) as a relevant fraction of morbidity and mortality among HIV-infected people twenty years after HAART introduction. The role of immunosuppression in the pathogenesis of NADCs is not well defined, and future researches should investigate the etiology of NADCs.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
April 2008
Department of Dermatology, SS Giovanni E Paolo Civil Hospital, Venice, Italy.
Objective: To evaluate the efficacy of botulinum toxin type-A (BoNTA) for the treatment of inverse psoriasis.
Background: The use of BoNTA in inverse psoriasis would be a novel approach compared with conventional treatments and may act at the neuroglandular junction level to reduce local sweating with its consequent skin maceration and secondary infection and at the extra-junction level to inhibit the liberation of neuropeptides and other pro-algogenic substances responsible for inflammation, hyperkeratosis and pain transmission.
Patients: Fifteen patients with a confirmed diagnosis of inverse psoriasis were enrolled into the study.